STAT44%
AIDS activists slam Biden R&D deal with Gilead over HIV prevention drug patents 59%
By Ed Silverman62%
7/13/2026, 8:58:46 PM
BS Summary: This article contains 10 faulty reasoning types, including Negativity Bias, Confirmation Bias, and Hasty Generalization, with Biased Writer Voice as the most egregious example at 54.7% saturation with 98 hits. Analysis detected 479 faulty-reasoning hits from 179 analyzed words, generating a BS Score of 55.6% and a BS Rank of 59% (8,966 of 21,886 articles). This article is worse (more manipulative) than 59.00% of the article peer group.
After more than a year of squabbling, a group of AIDS activists obtained an R&D agreement that was at the heart of a settlement between the U.S. government and Gilead Sciences over patents for HIV prevention drugs.
But in their view, the deal shows the Biden administration missed a “historic” opportunity to invest in — and expand access to — HIV prevention tools.
As noted previously, the settlement resolved a lawsuit that was filed six years ago by the previous Trump administration after the Centers for Disease Control and Prevention maintained that Gilead infringed on its patent rights.
The agency had helped fund academic research that later formed the basis for two Gilead HIV pills, Truvada and Descovy.
The administration had alleged that Gilead ignored the contributions by CDC scientists, exaggerated its own role in developing HIV prevention drugs, and refused to sign a licensing agreement despite “multiple attempts” at reaching a deal after unfairly reaping hundreds of millions of dollars from research funded by taxpayers.
Speakers
Loading…
Loading…
Loading…
Loading…
Analysis
Hover over highlighted words in the article to view the associated bias or fallacy analysis.